Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of RO7248824 In Participants With Angelman Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04428281
Recruitment Status : Recruiting
First Posted : June 11, 2020
Last Update Posted : July 28, 2020
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:

This is a Phase I, multicenter, non-randomized, adaptive, open label, multiple ascending, intra-participant, dose-escalation study using IT administration to investigate the safety, tolerability, PK and PD of RO7248824 in participants with AS.

Two linked sets of dose escalation cohorts are planned based on two different age groups, namely participants with AS aged ≥ 5 to ≤ 12 years in cohorts A1 to A4 (with at least 2 participants ≤ 8 years old in each cohort) and AS participants aged ≥ 1 to ≤ 4 years in cohorts B1 to B5. The two sets of cohorts will be run in parallel, with each cohort A1-A4 preceding and gating the linked cohort B1-B5 (e.g., A1 precedes B1).


Condition or disease Intervention/treatment Phase
Angelman Syndrome Drug: RO7248824 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 66 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Non-randomized, adaptive, open label, multiple ascending, intra-participant, dose-escalation study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of RO7248824 In Participants With Angelman Syndrome
Estimated Study Start Date : August 29, 2020
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Cohort A1 RO7248824
Participants 5-12 Years
Drug: RO7248824
RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration.

Experimental: Cohort A2 RO7248824
Participants 5-12 Years
Drug: RO7248824
RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration.

Experimental: Cohort A3 RO7248824
Participants 5-12 Years
Drug: RO7248824
RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration.

Experimental: Cohort A4 RO7248824
Participants 5-12 Years
Drug: RO7248824
RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration.

Experimental: Cohort B1 RO7248824
Participants 1-4 Years
Drug: RO7248824
RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration.

Experimental: Cohort B2 RO7248824
Participants 1-4 Years
Drug: RO7248824
RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration.

Experimental: Cohort B3 RO7248824
Participants 1-4 Years
Drug: RO7248824
RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration.

Experimental: Cohort B4 RO7248824
Participants 1-4 Years
Drug: RO7248824
RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration.

Experimental: Cohort B5 RO7248824
Participants 1-4 Years
Drug: RO7248824
RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration.




Primary Outcome Measures :
  1. Frequency And Severity Of Adverse Events [ Time Frame: Baseline to last visit (Day 365) or early withdrawal ]
  2. Frequency And Severity Of Serious Adverse Events [ Time Frame: Baseline to last visit (Day 365) or early withdrawal ]
  3. Number of Participants Discontinued Treatment due to Adverse Events [ Time Frame: Baseline to last visit (Day 365) or early withdrawal ]
  4. Frequency Of Abnormal Laboratory Findings (Blood And Cerebrospinal Fluid [CSF]) [ Time Frame: Baseline to last visit (Day 365) or early withdrawal ]
  5. Frequency Of Abnormal Vital Signs [ Time Frame: Baseline to last visit (Day 365) or early withdrawal ]
  6. Frequency Of Abnormal ECG Values [ Time Frame: Baseline to last visit (Day 365) or early withdrawal ]
  7. Mean Changes From Baseline in Temperature Over Time [ Time Frame: Baseline to last visit (Day 365) or early withdrawal ]
  8. Mean Changes From Baseline in Systolic Blood Pressure Over Time [ Time Frame: Baseline to last visit (Day 365) or early withdrawal ]
  9. Mean Changes From Baseline In Diastolic Blood Pressure Over Time [ Time Frame: Baseline to last visit (Day 365) or early withdrawal ]
  10. Mean Changes From Baseline In Heartrate Over Time [ Time Frame: Baseline to last visit (Day 365) or early withdrawal ]
  11. Mean Changes From Baseline In Respiratory Rate Over Time [ Time Frame: Baseline to last visit (Day 365) or early withdrawal ]

Secondary Outcome Measures :
  1. Time to Maximum Concentration (Tmax) for RO7248824 [ Time Frame: Day 1, 2, 15, 29, 30, 42, 56, 57, 70, 100, 224, 365 or early withdrawal ]
  2. Maximum Plasma Concentration Observed (Cmax) for RO7248824 [ Time Frame: Day 1, 2, 15, 29, 30, 42, 56, 57, 70, 100, 224, 365 or early withdrawal ]
  3. AUC From Time 0 To Time Of Last Sampling Point Or Last Quantifiable Sample, Whichever Comes First (AUC last) for RO7248824 [ Time Frame: Day 1, 2, 15, 29, 30, 42, 56, 57, 70, 100, 224, 365 or early withdrawal ]
  4. AUC From Time 0 To Infinity (AUCinf) for RO7248824 [ Time Frame: Day 1, 2, 15, 29, 30, 42, 56, 57, 70, 100, 224, 365 or early withdrawal ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The participant has a parent, caregiver or legal representative (hereinafter "caregiver") who is reliable, competent and at least 18 years of age. The caregiver is willing and able to accompany the participant to clinic visits and to be available to the Investigational Site by phone or email if needed and who (in the opinion of the investigator) is and will remain sufficiently knowledgeable of participant's ongoing condition to respond to any inquiries about the participant from personnel from the Study Site.
  • A caregiver must be able to consent for the participant according to International Council on Harmonisation (ICH) and local regulations.
  • Ability to comply with all study requirements.
  • Have adequate supportive psychosocial circumstances.
  • Able to tolerate blood draws.
  • Able to undergo LP and IT injection, under sedation or anesthesia if needed and as determined appropriate by the Investigator.
  • Stable medical status for at least 4 weeks prior to Screening and at the time of enrollment.
  • Body weight of ≥ 7 kg
  • Participant must be ≥ 1 to ≤ 12 years of age at the time of signing of the informed consent by the caregiver.
  • Clinical diagnosis of AS confirmed by a molecular diagnosis with genotypic classification of either UBE3A mutation of the maternal allele or deletion on the maternally inherited chromosome 15q11q13 that includes the UBE3A gene and is less than 7 Mb in size.

Reproductive Status:

Some of the provisions that follow may have limited applicability based on the age range of study participants (i.e., up to the age of 12) and the nature of the disease understudy. These provisions are nonetheless included for purposes of completeness in order:

Female Participants

A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

  • Women of non-childbearing potential.
  • Women of childbearing potential who agree to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods during the treatment period and for at least 6 months after the final dose of RO7248824. The following are acceptable contraceptive methods: bilateral tubal occlusion/ ligation, male sexual partner who is sterilized, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices and copper intrauterine devices, male or female condom with or without spermicide; and cap, diaphragm, or sponge with spermicide.

Male Participants

During the treatment period and for at least 6 months after the final dose of RO7248824, consent has to be provided to:

  • Remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures such as a condom, with a female partner of childbearing potential, or pregnant female partner, to avoid exposing the embryo.

The reliability of sexual abstinence for male and/or female enrollment eligibility needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of preventing drug exposure.

Exclusion Criteria:

Diagnostic Assessments

  • Clinically-significant laboratory, vital sign or electrocardiography (ECG) abnormalities at Screening

Type of Participants and Disease Characteristics

  • Molecular diagnosis of AS with genotypic classification:

UBE3A missense mutation of maternal allele Paternal Uniparental Disomy (UPD) of 15q11-13 UBE3A Imprinting center defect (ID) A partial molecular diagnosis of AS, that cannot exclude UPD or ID despite appropriate genetic testing.

Medical history and concurrent disease

  • Clinically relevant hematological, hepatic, cardiac or renal disease or event, in the judgement of the investigator. Pre-existing abnormal hepatic, renal or hematology lab tests must be discussed with the Sponsor Medical Monitor.
  • Any concomitant condition that might interfere with the clinical evaluation of AS and that is not related to AS.
  • Known history of human immunodeficiency virus (HIV) or hepatitis B virus (HBV) or hepatitis C virus (HCV).
  • Any condition that increases risk of meningitis.
  • History of bleeding diathesis or coagulopathy.
  • A medical history of brain or spinal disease that would interfere with the LP process, cerebrospinal fluid (CSF) circulation or safety assessment
  • History of clinically significant post-lumbar-puncture headache of moderate or severe intensity and/or blood patch
  • Malignancy within 5 years of Screening
  • Hospitalization for any major medical or surgical procedure involving general anesthesia within 12 weeks of Screening or planned during the study
  • Have any other conditions, which, in the opinion of the Investigator, would make the participant unsuitable for inclusion or could interfere with the participant participating in or completing the study, including any contraindication to administration of intrathecal therapy.
  • Premature birth with gestational age at birth below 34 weeks.
  • History of hypersensitivity to the investigational medicinal product (IMP), antisense oligonucleotides, or any excipients.

Prior Therapy

  • Allowed sleep medications have not been stable for 4 weeks prior to screening and at the time of enrollement.
  • Allowed medications for treatment of epilepsy have not been stable for 12 weeks prior to screening and at the time of enrollment.
  • Use of antiplatelet or anticoagulant therapy for 2 weeks prior to screening and at the time of enrollment.
  • Concurrent psychotropic medications have not been stable for 4 weeks prior to screening and at the time of enrollment.

Other Exclusion Criteria: Prior/Concurrent Clinical Study Experience

  • Received an investigational drug within 90 days or 5 times the half-life of the investigational drug (whichever is longer) or participation in a study testing an investigational medical device within 90 days prior to first dosing or if the device is still active.
  • Concurrent or planned concurrent participation in any clinical study (including observational and non-interventional studies) without approval of the Sponsor Medical Monitor. At the discretion of the Sponsor, participants may enroll into non-drug observational studies.
  • Previous participation in a cellular therapy, or gene therapy, or gene editing clinical study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04428281


Contacts
Layout table for location contacts
Contact: Reference Study ID Number: BP41674 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global-roche-genentech-trials@gene.com

Locations
Layout table for location information
United States, Illinois
Rush Medical Center Recruiting
Chicago, Illinois, United States, 60612
United States, Texas
Baylor College of Med; Texas Child Hosp; Pediactric Dept Not yet recruiting
Houston, Texas, United States, 77030
Italy
Ospedale Pediatrico Bambino Gesù; Dip. Neuroscienze e Neuroriabilitazione Not yet recruiting
Roma, Lazio, Italy, 00165
Spain
Corporacio Sanitaria Parc Tauli Not yet recruiting
Sabadell, Barcelona, Spain, 08208
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT04428281    
Other Study ID Numbers: BP41674
2019-003787-48 ( EudraCT Number )
RG6091 ( Other Identifier: RG Number )
First Posted: June 11, 2020    Key Record Dates
Last Update Posted: July 28, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Hoffmann-La Roche:
RO7248824; Angelman; ASO; LNA; Angelman syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Angelman Syndrome
Syndrome
Disease
Pathologic Processes
Movement Disorders
Central Nervous System Diseases
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn